Drug Trial Radar · NCT02515097
Safety and Efficacy of IDP-122 in Participants With Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
213
Actual
Start
Nov 5, 2015
Primary completion
Mar 15, 2017
Study completion Mar 15, 2017
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 4, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).
Conditions
- Plaque Psoriasis
Interventions
IDP-122 LotionDrug
Medicated topical lotion
IDP-122 Vehicle LotionDrug
Vehicle topical lotion with no active ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment Success at Week 8Time frame: Week 8
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Valeant Site 14
Santa Ana, California
Valeant Site 02
Boynton Beach, Florida
Valeant Site 10
Clearwater, Florida
Valeant Site 1
Tampa, Florida
Valeant Site 07
Plainfield, Indiana
Valeant Site 15
Olathe, Kansas
Valeant Site 08
Fridley, Minnesota
Valeant Site 13
Omaha, Nebraska
Valeant Site 04
New York, New York
Valeant Site 12
Stony Brook, New York
Valeant Site 05
High Point, North Carolina
Valeant Site 11
Knoxville, Tennessee
Valeant Site 03
Houston, Texas
Valeant Site 09
San Antonio, Texas
Valeant Site 06
West Jordan, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.